Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study. (April 2021) - Lüftner, D.; Tesch, H.; Schmidt, M.; Hartkopf, A.; Streicher, S.; Resch, A.; Genovese, L.; Rosé, C.; Valenti, R.; Harbeck, N.